Anxiolytic properties of the antipsychotic alkaloid alstonine

被引:38
作者
Costa-Campos, L
Dassoler, SC
Rigo, AP
Iwu, M
Elisabetsky, E
机构
[1] Univ Fed Rio Grande do Sul, ICBS, Curso Pos Grad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, ICBS, Lab Entofarmacol, BR-90040100 Porto Alegre, RS, Brazil
[3] Int Ctr Ethnomed & Drug Dev, BDCP, Nsukka, Nigeria
基金
美国国家卫生研究院;
关键词
alstonine; antipsychotics; anxiety; serotonin; glutamate; hole-board; light/dark; mice;
D O I
10.1016/j.pbb.2003.12.002
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Anxiolytic properties may be a crucial feature of newer antipsychotics associated with the improvement of negative symptoms in schizophrenic patients. The indole alkaloid alstonine acts as an atypical antipsychotic in behavioral models, but differs in its dopamine and serotonin binding profile. The purpose of this study was to verify if alstonine possesses anxiolytic properties in mice. The hole-board and light/dark models were used; moreover, the participation of D-1, 5-HT2, NMDA and gamma-aminobutyric acid (GABA) receptors was likewise investigated. Alstonine clearly behaves as anxiolytic in both hole-board and light/dark situations. Pretreatment with the 5-HT2A/2C serotonin receptor antagonist ritanserin reverted the effects of alstonine in both the hole-board and light/dark models, suggesting the involvement of these receptors in the alstonine mechanism of action. The involvement of glutamate NMDA receptors should also be considered, given that alstonine partially reversed the increase in locomotion induced by MK-801 in the hole board, as well as MK-801-induced hyperlocomotion in motor activity apparatus. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:481 / 489
页数:9
相关论文
共 76 条
[1]   Schizophrenia: the fundamental questions [J].
Andreasen, NC .
BRAIN RESEARCH REVIEWS, 2000, 31 (2-3) :106-112
[2]   M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro [J].
Arvanov, VL ;
Wang, RY .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (03) :197-209
[3]   WITHDRAWAL SYNDROME FOLLOWING SUBCHRONIC TREATMENT WITH ANXIOLYTIC AGENTS [J].
BARRY, JM ;
COSTALL, B ;
KELLY, ME ;
NAYLOR, RJ .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 27 (02) :239-245
[4]   Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety [J].
Belzung, C ;
Berton, F .
BEHAVIOURAL PHARMACOLOGY, 1997, 8 (6-7) :541-548
[5]   A comparative review of new antipsychotics [J].
Blin, O .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1999, 44 (03) :235-244
[6]   The mouse light/dark box test [J].
Bourin, M ;
Hascoët, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 463 (1-3) :55-65
[7]   Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice [J].
Bourin, M ;
Dhonnchadha, BAN ;
Colombel, MC ;
Dib, M ;
Hascoët, M .
BEHAVIOURAL BRAIN RESEARCH, 2001, 124 (01) :87-95
[8]   Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness [J].
Breese, GR ;
Knapp, DJ ;
Moy, SS .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2002, 26 (04) :441-455
[9]  
Bristow LJ, 1996, J PHARMACOL EXP THER, V277, P578
[10]   Dopamine D-4 receptor and anxiety: Behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze [J].
Cao, BJ ;
Rodgers, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 335 (2-3) :117-125